The European Respiratory Society (ERS) International Congress 2022

Bronchodilators ineffective in symptomatic, tobacco-exposed patients without COPD

Roshini Claire Anthony, 20221008110001

Bronchodilators, used in the treatment of chronic obstructive pulmonary disease (COPD), did not appear to benefit individuals with a history of smoking and respiratory symptoms who did not have airflow obstruction, results of the US-based RETHINC* study showed.

Brensocatib has no impact on COVID-19 clinical outcomes

Roshini Claire Anthony, 20221002110001

Results of the STOP-COVID trial, presented at ERS 2022, showed no clinical outcome benefit with the dipeptidyl peptidase-1 (DPP-1) inhibitor brensocatib compared with placebo in patients hospitalized with COVID-19 in the UK.

SVS endobronchial valve improves QoL in patients with emphysema

Audrey Abella, 20220926100000

In the 24-month follow-up results of the EMPROVE trial, treatment with the Spiration Valve System (SVS) endobronchial valve provided a sustained clinically significant benefit in disease-specific health-related quality of life (QoL) in patients with severe heterogeneous emphysema.

Inhaled IFN-β1a shows favourable signals for hospitalized COVID-19 patients

Audrey Abella, 20220922100000

In the phase III SPRINTER trial, inhaled interferon-beta-1a (IFN-β1a) showed encouraging signals for preventing disease progression or death in hospitalized COVID-19 patients.

Tezepelumab reduces mucus plugging in patients with asthma

Elaine Soliven, 20220922000000

In patients with uncontrolled, moderate-to-severe asthma, tezepelumab reduced mucus plugging, which was also tied to improvements in lung function parameters, according to an exploratory post hoc analysis of the CASCADE* trial presented at ERS 2022.

Antibiotics for COPD exacerbations: Aye or nay?

Elvira Manzano, 20220921000000

Antibiotics cannot be withheld in patients with chronic obstructive pulmonary disease (COPD) seeking treatment for acute moderate exacerbations, suggests findings from the ABACOPD study presented at ERS 2022. However, in one subgroup, it appeared antibiotics can be ruled out.

Remote smoking cessation programme delivers encouraging results in high-risk individuals

Roshini Claire Anthony, 20220920180001

A smoking cessation intervention delivered via telephone resulted in greater smoking cessation rates than usual care among individuals enrolled in targeted lung health screening, according to results of the QuLIT*2 study from the UK presented at ERS 2022.

Pirfenidone may benefit RA-ILD patients

Audrey Abella, 20220920100000

In the phase II TRAIL1 trial, oral pirfenidone slowed the rate of decline in lung function in individuals with rheumatoid arthritis-associated interstitial lung disease (RA-ILD).

Severe OSA doubles the risk of unprovoked VTE

Elvira Manzano, 20220920000000

Patients with obstructive sleep apnoea (OSA) who had the longest nocturnal hypoxaemia episodes have a twofold risk of developing venous thromboembolic events (VTE) in a study dubbed as the first to investigate the association between OSA and the incidence of unprovoked VTE.